(Reuters) – Moderna Inc said on Thursday it has dosed the first participant in a mid-to-late stage study testing its COVID-19 vaccine candidate in adolescents aged 12 to less than 18.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Sriraj Kalluvila)
